Generation Bio Co. (GBIO)
- Previous Close
3.0100 - Open
3.0600 - Bid 2.8700 x 400
- Ask 2.9300 x 200
- Day's Range
2.8500 - 3.1100 - 52 Week Range
0.8600 - 6.9800 - Volume
89,527 - Avg. Volume
242,062 - Market Cap (intraday)
192.784M - Beta (5Y Monthly) 2.79
- PE Ratio (TTM)
-- - EPS (TTM)
-1.9600 - Earnings Date May 8, 2024 - May 13, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
7.50
Generation Bio Co. develops non-viral genetic medicines for the treatment of rare and prevalent diseases. The company develops cell-targeted lipid nanoparticle (ctLNP) platform, a modular delivery system for nucleic acids to avoid off-target clearance by the liver and spleen that enables ctLNPs to persist in systemic circulation, which allows for highly selective and potent ligand-driven targeting to specific tissues and cell types; and novel immune-quiet DNA (iqDNA) to enable long-lasting high levels of gene expression from non-integrating episomes and avoids innate immune sensors that have long prevented DNA from use in non-viral systems. It uses its platform for developing a portfolio of programs for treating cancer, autoimmune, hematologic disorders, prioritizing sickle cell, beta-thalassemia, and hemophilia A diseases, as well as for other tissues and cell types, including retina, skeletal muscle, and central nervous system. The company was formerly known as Torus Therapeutics, Inc. and changed its name to Generation Bio Co. in November 2017. Generation Bio Co. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.
generationbio.comRecent News: GBIO
Performance Overview: GBIO
Trailing total returns as of 4/26/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: GBIO
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: GBIO
Valuation Measures
Market Cap
200.10M
Enterprise Value
33.63M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
32.88
Price/Book (mrq)
0.99
Enterprise Value/Revenue
5.70
Enterprise Value/EBITDA
-0.25
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-23.06%
Return on Equity (ttm)
-52.14%
Revenue (ttm)
5.9M
Net Income Avi to Common (ttm)
-126.61M
Diluted EPS (ttm)
-1.9600
Balance Sheet and Cash Flow
Total Cash (mrq)
264.36M
Total Debt/Equity (mrq)
48.19%
Levered Free Cash Flow (ttm)
-44.99M
Research Analysis: GBIO
Company Insights: GBIO
Fair Value
Dividend Score
Hiring Score
Insider Sentiment Score
Research Reports: GBIO
Daily – Vickers Top Insider Picks for 03/01/2024
The Vickers Top Insider Picks is a daily report that utilizes a proprietary algorithm to identify 25 companies with compelling insider purchase histories based on transactions over the past three months.
Daily – Vickers Top Insider Picks for 02/29/2024
The Vickers Top Insider Picks is a daily report that utilizes a proprietary algorithm to identify 25 companies with compelling insider purchase histories based on transactions over the past three months.
Daily – Vickers Top Insider Picks for 02/28/2024
The Vickers Top Insider Picks is a daily report that utilizes a proprietary algorithm to identify 25 companies with compelling insider purchase histories based on transactions over the past three months.
Daily – Vickers Top Insider Picks for 02/27/2024
The Vickers Top Insider Picks is a daily report that utilizes a proprietary algorithm to identify 25 companies with compelling insider purchase histories based on transactions over the past three months.